LPL Financial’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

LPL Financial’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-38,780	Closed	-$798K	–	4823
2023 Q2	$798K	Sell	38,780 -16,472	-30%	-$345K	﹤0.01%	3037
2023 Q1	$1.13M	Buy	55,252 +1,661	+3%	+$37.2K	﹤0.01%	2661
2022 Q4	$1.2M	Sell	53,591 -7,685	-13%	-$173K	﹤0.01%	2503
2022 Q3	$1.27M	Buy	61,276 +2,149	+4%	+$52.3K	﹤0.01%	2347
2022 Q2	$1.38M	Buy	59,127 +1,642	+3%	+$39.1K	﹤0.01%	2317
2022 Q1	$1.57M	Sell	57,485 -2,158	-4%	-$60.8K	﹤0.01%	2237
2021 Q4	$2.13M	Sell	59,643 -2	-0%	-$75	﹤0.01%	2045
2021 Q3	$2.45M	Buy	59,645 +520	+0.9%	+$21.9K	﹤0.01%	1897
2021 Q2	$2.37M	Buy	59,125 +20,263	+52%	+$756K	﹤0.01%	1837
2021 Q1	$1.38M	Buy	38,862 +11,916	+44%	+$447K	﹤0.01%	2126
2020 Q4	$838K	Buy	+26,946	New	+$820K	﹤0.01%	2329

Other funds holding GERM

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

CHC

City Holding Co Charleston, West Virginia $884M AUM 27.52% 1-Year Est. Return

BAM

Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return

LPL Financial's GERM Position: Q3 2023 in Review

LPL Financial sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2023, closing a stake of 38,780 shares — an estimated $798K sold.

LPL Financial first reported a position in GERM in Q4 2020 and held it in 11 quarters. The position peaked at $2.45M in Q3 2021. 17 funds tracked by Wall St. Rank hold GERM as of Q3 2023.

LPL Financial reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2023 after selling out during the quarter.
LPL Financial sold 38,780 Amplify Treatments, Testing and Advancements ETF shares in Q3 2023, an estimated $798K.
LPL Financial first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2020 and held it in 11 quarters.
LPL Financial's Amplify Treatments, Testing and Advancements ETF position peaked at $2.45M in Q3 2021.
17 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2023.

Based on LPL Financial's 13F filing for Q3 2023, filed 13 Nov 2023.